# TriSalus Life Sciences, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/TriSalus Life Sciences, Inc.). ## Overview TriSalus Life Sciences is a U.S.-based medical device company focused on catheter-based infusion systems used in interventional oncology procedures. Its core product platform, TriNav, is designed for delivery in embolization workflows and is sold directly to hospitals, clinics, and physicians in the United States. ## Products & services • TriNav infusion catheter system • PEDD infusion systems for embolization procedures • Direct hospital and clinic sales • Clinical education and technical support • Reimbursement and procedure support - **TriNav infusion devices** (90%) — Catheter-based infusion devices used in embolization procedures, primarily TriNav. - **PEDD infusion systems** (10%) — Infusion systems sold for interventional radiology and oncology procedures. - TriNav infusion catheter system - PEDD infusion systems for embolization procedures - Direct hospital and clinic sales - Clinical education and technical support - Reimbursement and procedure support ## Customers TriSalus sells directly to hospitals, clinics, and ambulatory surgery centers that perform embolization procedures, especially interventional radiology and oncology departments. The buying decision often involves physicians, interventional radiologists, medical oncologists, nursing staff, and value analysis committees that evaluate clinical utility and purchasing economics. - **Hospitals and academic medical centers** (primary) — Buy TriNav for embolization procedures and evaluate it through clinical and procurement committees. - **Interventional radiologists** (primary) — Use the device in TACE, TARE, and related procedures and influence adoption. - **Medical oncologists and oncology teams** (secondary) — Support treatment planning for liver cancer patients and may recommend use. - **Ambulatory surgery centers and clinics** (secondary) — Purchase devices for outpatient or clinic-based interventional procedures. - **Value Analysis Committees** (primary) — Review clinical and economic justification before hospital adoption. - Hospitals performing TACE, TARE, and other embolization procedures - Interventional radiologists who use the catheter in procedures - Medical oncologists involved in liver cancer treatment pathways - Value Analysis Committees that approve hospital purchases - Ambulatory surgery centers and clinics buying directly ## Geography TriSalus is headquartered in Westminster, Colorado and sells primarily in the United States through a direct sales force. The company’s commercial focus is nationwide, with emphasis on hospitals and major academic medical centers that perform higher volumes of embolization procedures. - **United States** (100%) — Company disclosures describe direct sales nationwide in the U.S.; no country split was provided. - Headquartered in Westminster, Colorado - Primary market is the United States - Direct sales model reaches hospitals nationwide - Focus on major academic medical centers and procedure-heavy hospitals ## Strategy TriSalus’ strategy centers on expanding adoption of TriNav among interventional radiologists and hospital systems through direct clinical engagement and education. The company also emphasizes support services, including reimbursement and technical assistance, to reduce adoption friction and strengthen its position in procedure-based purchasing decisions. - **Expand TriNav adoption in embolization procedures** (short-term) — Procedure volume and physician familiarity drive recurring device usage. - **Strengthen hospital and clinician relationships** (short-term) — Hospital purchasing depends on clinical trust and committee approval. - **Support broader interventional oncology positioning** (medium-term) — Clinical and advocacy relationships can widen awareness and use cases. - Drive TriNav adoption through direct physician and hospital engagement - Target high-volume embolization centers and academic medical centers - Use clinical education to improve product understanding and utilization - Provide reimbursement and technical support to reduce adoption barriers - Build relationships with advocacy groups and liver cancer communities ## Risks TriSalus faces the risks typical of an early-stage medical device company, including customer concentration, limited contractual lock-in, and dependence on physician adoption. Its business is also exposed to regulatory, reimbursement, product liability, cybersecurity, and supply-chain risks, while ongoing losses and capital needs can constrain execution. - **Customer termination and weak contractual lock-in** [high] — Many agreements are not long-term and some consignment deals can be ended with short notice. - **Dependence on physician adoption** [high] — Interventional radiologists and hospital committees influence whether TriNav is used. - **Competitive and technological change** [medium] — The medical device market changes quickly and larger competitors may offer alternatives. - **Regulatory and reimbursement risk** [high] — Device use and hospital economics depend on healthcare regulation and payment support. - **Supply-chain and cybersecurity disruption** [medium] — The company relies on third parties for manufacturing, systems, and clinical operations. - **Financing and liquidity risk** [high] — The company has not yet generated enough cash from operations to fund growth. - Customers can terminate consignment or purchase relationships with limited notice - Revenue depends on physician adoption and procedure volumes - Medical device competition and rapid technology change can pressure adoption - Regulatory, reimbursement, and product liability risks affect commercialization - Ongoing capital needs create financing and execution risk ## Accounting Revenue is recognized when TriNav devices are shipped or when control transfers under consignment arrangements, so timing can vary with delivery and clinical use. Investors should also watch rebates, fair value remeasurements of financing-related liabilities, and estimates tied to product costs and contingent obligations, all of which can move reported results materially. - **Revenue recognition on consignment and direct sales** — Can shift revenue between periods - **Customer rebates** — Reduces net sales and can affect quarterly comparability - **Fair value of SEPA, warrant, and earnout liabilities** — Can materially affect reported net loss - **Manufacturing cost and inventory estimates** — Affects gross margin and operating leverage - Revenue recognition depends on shipment or transfer of control - Consignment arrangements can delay revenue until clinical use - Customer rebates reduce revenue when performance conditions are met - Fair value changes on warrants and earnout liabilities affect earnings - Inventory and manufacturing cost estimates affect gross margin --- *Last updated: 2026-04-29T05:04:27.709680+00:00*